AIMS: The activity of the transcription factor c-Myc is dependent upon heterodimerization with Max to control target gene transcription. Small-molecule inhibitors of c-Myc-Max have exhibited low potency and poor water solubility and are therefore unsuitable for in vivo application. We hypothesized that a nanomedicine approach incorporating a cryptic c-Myc inhibitor prodrug could be delivered and enzymatically released in order to effectively inhibit melanoma. MATERIALS & METHODS: An Sn-2 lipase-labile Myc inhibitor prodrug was synthesized and included in two αvβ3-targeted nanoparticle platforms (20 and 200 nm). The inherent antiproliferate potency was compared with the lipid-free compound using human and mouse melanoma cell lines. RESULTS & CONCLUSION: These data demonstrate for the first time a successful nanodelivery of c-Myc inhibitors and their potential use to prevent melanoma.
AIMS: The activity of the transcription factor c-Myc is dependent upon heterodimerization with Max to control target gene transcription. Small-molecule inhibitors of c-Myc-Max have exhibited low potency and poor water solubility and are therefore unsuitable for in vivo application. We hypothesized that a nanomedicine approach incorporating a cryptic c-Myc inhibitor prodrug could be delivered and enzymatically released in order to effectively inhibit melanoma. MATERIALS & METHODS: An Sn-2 lipase-labile Myc inhibitor prodrug was synthesized and included in two αvβ3-targeted nanoparticle platforms (20 and 200 nm). The inherent antiproliferate potency was compared with the lipid-free compound using human and mousemelanoma cell lines. RESULTS & CONCLUSION: These data demonstrate for the first time a successful nanodelivery of c-Myc inhibitors and their potential use to prevent melanoma.
Authors: Shelton D Caruthers; Tillmann Cyrus; Patrick M Winter; Samuel A Wickline; Gregory M Lanza Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2009 May-Jun
Authors: Huabo Wang; Dalia I Hammoudeh; Ariele Viacava Follis; Brian E Reese; John S Lazo; Steven J Metallo; Edward V Prochownik Journal: Mol Cancer Ther Date: 2007-09 Impact factor: 6.261
Authors: Gabriela Mustata; Ariele Viacava Follis; Dalia I Hammoudeh; Steven J Metallo; Huabo Wang; Edward V Prochownik; John S Lazo; Ivet Bahar Journal: J Med Chem Date: 2009-03-12 Impact factor: 7.446
Authors: Rebecca Cotterman; Victor X Jin; Sheryl R Krig; Jessica M Lemen; Alice Wey; Peggy J Farnham; Paul S Knoepfler Journal: Cancer Res Date: 2008-12-01 Impact factor: 12.701
Authors: Michele Herneisey; Jonathan Williams; Janja Mirtic; Lu Liu; Sneha Potdar; Christina Bagia; Jane E Cavanaugh; Jelena M Janjic Journal: Ther Deliv Date: 2016-11-11
Authors: A W L Bayci; D A Baker; A E Somerset; O Turkoglu; Z Hothem; R E Callahan; R Mandal; B Han; T Bjorndahl; D Wishart; R Bahado-Singh; S F Graham; R Keidan Journal: Metabolomics Date: 2018-08-03 Impact factor: 4.290
Authors: Deepti Soodgupta; Dipanjan Pan; Grace Cui; Angana Senpan; Xiaoxia Yang; Lan Lu; Katherine N Weilbaecher; Edward V Prochownik; Gregory M Lanza; Michael H Tomasson Journal: Mol Cancer Ther Date: 2015-03-30 Impact factor: 6.261
Authors: Dipanjan Pan; Christine T N Pham; Katherine N Weilbaecher; Michael H Tomasson; Samuel A Wickline; Gregory M Lanza Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2015-08-21
Authors: Alison K Esser; Michael H Ross; Francesca Fontana; Xinming Su; Ariel Gabay; Gregory C Fox; Yalin Xu; Jingyu Xiang; Anne H Schmieder; Xiaoxia Yang; Grace Cui; Michael Scott; Samuel Achilefu; Jay Chauhan; Steven Fletcher; Gregory M Lanza; Katherine N Weilbaecher Journal: Theranostics Date: 2020-06-12 Impact factor: 11.556
Authors: Fabiana M Meliso; Danilo Micali; Camila T Silva; Thaís S Sabedot; Simon G Coetzee; Adrian Koch; Fabian B Fahlbusch; Houtan Noushmehr; Regine Schneider-Stock; Miriam G Jasiulionis Journal: Oncotarget Date: 2017-10-03